The stock of Relay Therapeutics Inc (RLAY) has gone down by -10.00% for the week, with a -17.20% drop in the past month and a -40.40% drop in the past quarter. The volatility ratio for the week is 5.99%, and the volatility levels for the past 30 days are 5.60% for RLAY. The simple moving average for the past 20 days is -16.58% for RLAY’s stock, with a -34.72% simple moving average for the past 200 days.
Is It Worth Investing in Relay Therapeutics Inc (NASDAQ: RLAY) Right Now?
Company’s 36-month beta value is 1.67.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RLAY is 92.21M, and currently, short sellers hold a 12.12% ratio of that floaft. The average trading volume of RLAY on April 18, 2024 was 1.13M shares.
RLAY) stock’s latest price update
The stock price of Relay Therapeutics Inc (NASDAQ: RLAY) has plunged by -7.86 when compared to previous closing price of 6.74, but the company has seen a -10.00% decline in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-04-11 that CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in three upcoming fireside chats: Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024 at 1:00 p.m.
Analysts’ Opinion of RLAY
Many brokerage firms have already submitted their reports for RLAY stocks, with Jefferies repeating the rating for RLAY by listing it as a “Hold.” The predicted price for RLAY in the upcoming period, according to Jefferies is $12.50 based on the research report published on April 20, 2023 of the previous year 2023.
Raymond James, on the other hand, stated in their research note that they expect to see RLAY reach a price target of $29. The rating they have provided for RLAY stocks is “Strong Buy” according to the report published on April 19th, 2023.
Raymond James gave a rating of “Outperform” to RLAY, setting the target price at $29 in the report published on April 13th of the previous year.
RLAY Trading at -29.13% from the 50-Day Moving Average
After a stumble in the market that brought RLAY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.10% of loss for the given period.
Volatility was left at 5.60%, however, over the last 30 days, the volatility rate increased by 5.99%, as shares sank -20.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.54% lower at present.
During the last 5 trading sessions, RLAY fell by -10.00%, which changed the moving average for the period of 200-days by -50.56% in comparison to the 20-day moving average, which settled at $7.37. In addition, Relay Therapeutics Inc saw -43.60% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RLAY starting from Bergstrom Donald A, who sale 765 shares at the price of $7.70 back on Mar 27 ’24. After this action, Bergstrom Donald A now owns 530,113 shares of Relay Therapeutics Inc, valued at $5,890 using the latest closing price.
Catinazzo Thomas, the Chief Financial Officer of Relay Therapeutics Inc, sale 348 shares at $7.70 during a trade that took place back on Mar 27 ’24, which means that Catinazzo Thomas is holding 341,498 shares at $2,680 based on the most recent closing price.
Stock Fundamentals for RLAY
Current profitability levels for the company are sitting at:
- -14.6 for the present operating margin
- 0.79 for the gross margin
The net margin for Relay Therapeutics Inc stands at -13.11. The total capital return value is set at -0.46. Equity return is now at value -40.18, with -35.19 for asset returns.
Based on Relay Therapeutics Inc (RLAY), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -5.62.
Currently, EBITDA for the company is -380.57 million with net debt to EBITDA at 0.24. When we switch over and look at the enterprise to sales, we see a ratio of 28.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 25.44.
Conclusion
In a nutshell, Relay Therapeutics Inc (RLAY) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
